Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recombinant adenovirus serotype 5 (rAd5) vaccine vectors for human immunodeficiency virus type 1 (HIV-1) and other pathogens have been shown to elicit antigen-specific cellular immune responses. Rare serotype rAd vectors have also been constructed to circumvent preexisting anti-Ad5 immunity and to facilitate the development of novel heterologous rAd prime-boost regimens. Here we show that rAd5, rAd26, and rAd48 vectors elicit qualitatively distinct phenotypes of cellular immune responses in rhesus monkeys and can be combined as potent heterologous prime-boost vaccine regimens. While rAd5-Gag induced primarily gamma interferon-positive (IFN-γ + ) and IFN-γ + /tumor necrosis factor alpha + (TNF-α + ) T-lymphocyte responses, rAd26-Gag and rAd48-Gag induced higher proportions of interleukin-2 + (IL-2 + ) and polyfunctional IFN-γ + /TNF-α + /IL-2 + T-lymphocyte responses. Priming with the rare serotype rAd vectors proved remarkably effective for subsequent boosting with rAd5 vectors. These data demonstrate that the rare serotype rAd vectors elicited T-lymphocyte responses that were phenotypically distinct from those elicited by rAd5 vectors and suggest the functional relevance of polyfunctional CD8 + and CD4 + T-lymphocyte responses. Moreover, qualitative differences in cellular immune responses may prove critical in determining the overall potency of heterologous rAd prime-boost regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“Tetrameric H-2Db complexes folded around the immunodominant SIV Gag AL11 epitope (AAVKNWMTQTL) (3) were prepared and utilized to stain peptide-specific CD8 T lymphocytes from C57BL/6 mice as described previously ( 2 , 3). Mouse blood was collected in RPMI 1640 containing 40 U/ml heparin.”
MethodSelf-citationCD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635 · cited 1×
“In particular, “helped” CD8 T lymphocytes primed in the presence of adequate CD4 T-cell help were able to expand much more efficiently following subsequent boost immunizations than “helpless” CD8 T lymphocytes primed without CD4 T-cell help (9, 24, 29).”
BackgroundDefective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213 · cited 1×
“In particular, “helped” CD8 T lymphocytes primed in the presence of adequate CD4 T-cell help were able to expand much more efficiently following subsequent boost immunizations than “helpless” CD8 T lymphocytes primed without CD4 T-cell help (9, 24, 29).”
BackgroundDevelopment and Homeostasis of T Cell Memory in Rhesus Macaque
Pitcher, C. J., Hagen, S. I., Walker, J. M., Lum, R., Mitchell, B. L., Maino, V. C., Axthelm, M. K., & Picker, L. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.29 · Cited by 467 · cited 1×
“CM and EM T lymphocytes were defined, respectively, as CD28 CD95 and CD28 CD95 T lymphocytes (17, 19).”
Background
Cited by
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927
“33 Given that we see a substantial increase in immune titers after a second dose, we do not believe that a neutralizing anti-PEG response affects the LNP-based vaccines we describe here.”
Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Self-citationVaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Barouch, D. H., Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., Iampietro, M. J., SanMiguel, A., Seaman, M. S., Ferrari, G., et al. (2012) · Nature · doi:10.1038/nature10766 · Cited by 465
Self-citationImmune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Liu, J., O’Brien, K. L., Lynch, D. M., Simmons, N. L., La Porte, A., Riggs, A. M., Abbink, P., Coffey, R. T., Grandpre, L. E., Seaman, M. S., et al. (2009) · Nature · doi:10.1038/nature07469 · Cited by 452
Self-citationEmerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
Fernandes, Q., Inchakalody, V. P., Merhi, M., Mestiri, S., Taib, N., Moustafa Abo El-Ella, D., Bedhiafi, T., Raza, A., Al-Zaidan, L., Mohsen, M. O., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2031274 · Cited by 447
Electroporation delivery of DNA vaccines: prospects for success
Sardesai, N. Y., & Weiner, D. B. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.008 · Cited by 416
Challenges in the development of an HIV-1 vaccine
Barouch, D. H. (2008) · Nature · doi:10.1038/nature07352 · Cited by 380
Self-citationSputnik V COVID-19 vaccine candidate appears safe and effective
Jones, I., & Roy, P. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00191-4 · Cited by 379
Viruses as vaccine vectors for infectious diseases and cancer
Draper, S. J., & Heeney, J. L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 353
(2020) · npj Vaccines · doi:10.1038/s41541-020-00243-x · Cited by 351
Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.4218 · Cited by 324
Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., Clark, S., Ng’ang’a, D., Brandariz, K. L., Abbink, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.025 · Cited by 305
Self-citationColloca, S., Barnes, E., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002925 · Cited by 300
New Insights on Adenovirus as Vaccine Vectors
Lasaro, M. O., & Ertl, H. C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.130 · Cited by 263
Novel Vaccines to Human Rabies
Ertl, H. C. J. (2009) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000515 · Cited by 93
“Examples of such rare serotypes include AdHu35, AdHu48, AdHu11, or AdHu26 viruses, and vectors based on these serotypes have been tested for antigens of HIV-1 or tuberculosis [88,89], but not yet for those of rabies virus.”
Background
Metadata
- Authors
- Liu, J., Ewald, B. A., Lynch, D. M., Denholtz, M., Abbink, P., Lemckert, A. A. C., Carville, A., Mansfield, K. G., Havenga, M. J., Goudsmit, J., & Barouch, D. H.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2008-05-15
- Volume
- 82
- Issue
- 10
- Pages
- 4844-4852
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2133957204
- Cited by
- 130
- References
- 4
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.